pSivida spins off nanotech diagnostics company
This article was originally published in Clinica
Australian nanotechnology company pSivida has created a new subsidiary, AION Diagnostics, which will focus on developing products from the company's BioSilicon platform technology. The spin-off, funded through a private investment of Aus$1.2m ($0.85m) by pSivida, will enable the Perth-based company to focus on other core areas such as slow release drug delivery and brachytherapy.
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.